➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
Baxter
Johnson and Johnson
Mallinckrodt

Last Updated: January 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ipatasertib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Ipatasertib?

Ipatasertib is an investigational drug.

There have been 34 clinical trials for Ipatasertib. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2020.

The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and SOLTI Breast Cancer Research Group.

There are twenty-six US patents protecting this investigational drug and four hundred and forty-four international patents.

Recent Clinical Trials for Ipatasertib
TitleSponsorPhase
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseGenentech, Inc.Phase 2
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase InhibitorHoffmann-La RochePhase 3
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase InhibitorCanadian Cancer Trials GroupPhase 3

See all Ipatasertib clinical trials

Clinical Trial Summary for Ipatasertib

Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib

See all Ipatasertib clinical trials

US Patents for Ipatasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ipatasertib   Start Trial Polymeric nanoparticles and methods of making and using same Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY)   Start Trial
Ipatasertib   Start Trial Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use GENENTECH, INC. (South San Francisco, CA)   Start Trial
Ipatasertib   Start Trial Processes for the preparation of pyrimidinylcyclopentane compounds GENENTECH, INC. (South San Francisco, CA)   Start Trial
Ipatasertib   Start Trial Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds GENENTECH INC. (South San Francisco, CA) F. HOFFMANN-LA ROCHE AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ipatasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Ipatasertib European Patent Office EP3119395 2034-03-17   Start Trial
Ipatasertib World Intellectual Property Organization (WIPO) WO2015142605 2034-03-17   Start Trial
Ipatasertib Australia AU2012236135 2031-04-01   Start Trial
Ipatasertib Australia AU2012236138 2031-04-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
Baxter
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.